Claims for Patent: 6,475,780

Summary for Patent: 6,475,780

Title:	Alphavirus vectors for paramyxovirus vaccines
Abstract:	A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.
Inventor(s):	Parrington; Mark (Bradford, CA), Li; Xiaomao (Toronto, CA), Klein; Michel H. (Toronto, CA)
Assignee:	Aventis Pasteur Limited (Toronto, CA)
Application Number:	09/554,337
Patent Claims:	1. A vector, comprising: a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit in vivo replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that elicits the generation of antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being under transcriptional control of a promoter; a third nucleotide sequence located between the first nucleotide sequence and the promoter sequence and comprising a pair of splice sites to prevent aberrant mRNA splicing; and a fourth nucleotide sequence which is a hepatitis delta virus ribozyme sequence at the 3'-end of the first nucleotide sequence to ensure proper in vivo cleavage at the 3'-end of the first nucleotide sequence. 2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). 3. The vector of claim 2 wherein the PIV protein is seletected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4. 4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3. 5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV. 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G protein. 7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G protein lacking the transmembrane anchor and cytoplasmic tail. 8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus. 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI. 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter. 11. The vector of claim 1 wherein said third nucleotide sequence is that of rabbit .beta.-globin intron II. 12. The vector of claim 1 wherein said promoter sequence is an immediate early cytomegalovirus (CMV) promoter and the human cytomegalovirus Intron A sequence is provided downstream of the promoter and upstream of the third nucleotide sequence. 13. The vector of claim 1 which is plasmid pMP44 shown in FIG. 2D. 14. The vector of claim 1 which consists of SEQ ID No: 1. 15. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncial virus (RSV), which comprises: isolating a first DNA sequence encoding an RSV F or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; inserting a third DNA sequence into the vector between the first DNA sequence and the second DNA sequence, said third DNA sequence comprising a pair of splice sites to prevent aberrant mRNA splicing: locating a fourth nucleotide sequence which is a hepatitis delta virus ribozyme sequence in the vector at the 3'-end of the first DNA sequence to ensure proper in vivo cleavage at the 3'-end of the first DNA sequence; and formulating the vector as a vaccine for in vivo administration. 16. The method of claim 15 wherein said vector is pMP44 shown in FIG. 2D. 17. The method of claim 15 wherein said vector consists of SEQ ID no: 1.

Details for Patent 6,475,780

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-11-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-11-14
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-11-14